Nebenwirkungen · Oslif Breezhaler
Oslif Breezhaler 150 microgram inhalation powder, hard capsules Oslif Breezhaler 300 microgram inhalation powder, hard capsules · Abschnitt 4.8 · PDF-Seite 6
HOS-212855 · Präparat HOS-154990
The Oslif Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD. 4 764 patients were exposed to indacaterol up to one year at doses up to twice the maximum recommended dose. Of these patients, 2 611 were on treatment with 150 microgram once daily and 1 157 on treatment with 300 microgram once daily. Approximately 41% of patients had severe COPD. The mean age of patients was 64 years, with 48% of patients aged 65 years or older, and the majority (80%) was Caucasian.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T17:00:00Z · SHA-256 18b46cd9126c7d9a7f204bb67d49f1ba5702f381cf921b9f1b5dce688eb9c1ed · Passage 8174323fca3e9f2819058282ecdff48c0b25e5c547f844dcd69d599b6ceaa2c7 · Zeichen 1006–1544 im Abschnitt